Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on March 11, 2022. The filing serves to announce the Company's financial results for the fiscal year ended December 31, 2021. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "JAGX."
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that a press release containing these details has been issued. The specific financial data is contained in Exhibit 99.1 (Press Release, dated March 11, 2022), which is furnished but not included in the text of this 8-K summary.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the body of the report. Investors must refer to the attached press release (Exhibit 99.1) for a comparison of 2021 results against prior periods.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the accompanying press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section or incorporated by reference into other Company filings unless expressly referenced. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Key Facts for Investor Verification
- Verify the specific 2021 financial results (revenue, net loss, cash position) by reviewing the press release attached as Exhibit 99.1.
- Confirm that the 8-K filing itself does not constitute a "filed" document for liability purposes regarding the financial data, per the disclaimer in Item 2.02.
- Check the Company's status as an emerging growth company, as indicated by the check mark in the filing.
- Review the signature block to confirm the report was authorized by Lisa A. Conte, President and Chief Executive Officer.